Literature DB >> 3311444

Interaction of cimetidine with oral melphalan. A pharmacokinetic study.

L Sviland1, A Robinson, S J Proctor, D N Bateman.   

Abstract

The effects of pretreatment with cimetidine (200 mg three times daily, 400 mg at night) on the pharmacokinetics of oral melphalan (10 mg) have been investigated in patients with multiple myeloma. Cimetidine pretreatment reduced the bioavailability of oral melphalan by approximately 30% (P less than 0.05). The elimination rate of melphalan from plasma was significantly increased by cimetidine (P less than 0.05), the half-life being reduced from 1.94 +/- 0.55 h to 1.57 +/- 0.53 h. Cimetidine appeared to reduce the interindividual variability in melphalan absorption, but at the cost of reduced bioavailability.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3311444     DOI: 10.1007/BF00253974

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  6 in total

1.  Stability of melphalan solutions during preparation and storage.

Authors:  A G Bosanquet
Journal:  J Pharm Sci       Date:  1985-03       Impact factor: 3.534

2.  The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen.

Authors:  K W Woodhouse; P Hamilton; A Lennard; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Oral melphalan kinetics.

Authors:  D S Alberts; S Y Chang; H S Chen; T L Evans; T E Moon
Journal:  Clin Pharmacol Ther       Date:  1979-12       Impact factor: 6.875

4.  High-pressure liquid chromatographic analysis of melphalan in plasma.

Authors:  S Y Chang; D S Alberts; L R Melnick; P D Walson; S E Salmon
Journal:  J Pharm Sci       Date:  1978-05       Impact factor: 3.534

5.  Kinetics of intravenous melphalan.

Authors:  D S Alberts; S Y Chang; H S Chen; T E Moon; T L Evans; R L Furner; K Himmelstein; J F Gross
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

6.  Reduction of liver blood flow and propranolol metabolism by cimetidine.

Authors:  J Feely; G R Wilkinson; A J Wood
Journal:  N Engl J Med       Date:  1981-03-19       Impact factor: 91.245

  6 in total
  4 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

2.  The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.

Authors:  U Loos; E Musch; M Engel; J H Hartlapp; E Hügl; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  The interaction between oral melphalan and gastric antisecretory drugs: Impact on clinical efficacy and toxicity.

Authors:  Fumiaki Kitazawa; Yoko Kado; Kumi Ueda; Takatoshi Kokufu; Shin-Ichi Fuchida; Akira Okano; Mayumi Hatsuse; Satoshi Murakami; Yuko Nakayama; Kohji Takara; Chihiro Shimazaki
Journal:  Mol Clin Oncol       Date:  2015-11-20

Review 4.  Antineoplastic agents. Drug interactions of clinical significance.

Authors:  E van Meerten; J Verweij; J H Schellens
Journal:  Drug Saf       Date:  1995-03       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.